dr. o’regan on the utility of cdk4/6 inhibitors in breast cancer
Published 4 years ago • 74 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:42
dr. o'regan on biomarkers of response to cdk4/6 inhibitors in breast cancer
-
1:13
dr. o'regan on emerging cdk4/6 combinations in breast cancer
-
1:11
dr. accordino on the utility of cdk4/6 inhibitors in hr /her2– breast cancer
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
1:10
dr. o'regan on future of chemotherapy in breast cancer
-
1:18
dr. yardley on the utility of cdk4/6 inhibitors in metastatic hr breast cancer
-
12:30
dr. ruth o'regan | san antonio breast cancer symposium 2022 | debate on cdk46 inhibitors
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
6:36
adjuvant cdk4/6 inhibition in early-stage hr-positive breast cancer | ruth o'regan
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
1:01
dr. o’regan on biosimilar education in breast cancer
-
1:44
dr. evans on the tolerability of cdk4/6 inhibitors in hr breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer
-
6:11
hr metastatic breast cancer: upfront cdk4/6 inhibition
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
3:50
cdk4/6 inhibitors in metastatic breast cancer
-
8:28
cdk4/6 inhibition in breast cancer
-
0:49
dr. o'regan on biomarker research in breast cancer